Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | PRKCA | P17252 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 7/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285196 | 0.81 | NUDT1 (0.33) | JAK2CYP17A1CYP1A2JAK3 | |
| SCHEMBL2675096 | 0.72 | PRKCQ (0.60) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL292279 | 0.70 | PRKCQ (0.68) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL292289 | 0.68 | FEN1 (0.41) | JAK2PRKCQCYP17A1CYP1A2JAK3 | |
| SCHEMBL5956817 | 0.67 | NCF1 (0.39) | CYP17A1CYP1A2 | |
| SCHEMBL285259 | 0.67 | CYP17A1 (0.35) | CYP17A1CYP1A2 | |
| SCHEMBL293663 | 0.66 | AURKA (0.44) | ROCK2ROCK1CYP17A1CYP1A2GSK3B | |
| SCHEMBL285565 | 0.64 | KDM4E (0.42) | — | |
| SCHEMBL285644 | 0.63 | PRKCQ (0.43) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL30668855 | 0.62 | KDM4E (0.54) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8727522-B2 | Ultraviolet crosslinking ink and inkjet recording method | RICOH COMPANY, LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120176456-A1 | ULTRAVIOLET CROSSLINKING INK AND INKJET RECORDING METHOD | RICOH COMPANY, LTD., (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2427464-A1 | PYRAZOLOPYRIDINES | Vertex Pharmaceuticals Incorporated (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129668-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178778-A1 | PYRAZOLOPYRIDINES | MAP3K5, MAP4K5, MAP3K20 | JAK2 230/4885ROCK2 370/4885PRKCQ 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.